Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cisco Systems Inc (CSCO) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Cisco Systems IncTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Cisco Systems Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Cisco Systems Inc trades at $121.24 (market cap $483.10B), while Regeneron Pharmaceuticals Inc trades at $796.32 (market cap $83.19B). The key difference: Cisco Systems Inc is far larger — about 5.8× Regeneron Pharmaceuticals Inc's market cap, and Cisco Systems Inc pays the higher dividend (1.37%). Which is the better fit depends on your goals.

CSCOREGN
Market Cap
$483.10B$83.19B
Volume
22,887,319
Sector
TechnologyHealth
52-Week High
$130.00$812.27
52-Week Low
$66.20$555.51
Enterprise Value
$497.76B$77.90B
Dividend Yield
1.37%0.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cisco Systems Inc

Cisco Systems (CSCO) trades at $120.43, down 0.82% on the day, amid a bullish technical outlook and strong earnings beats. The stock shows robust fundamentals with a 64.33% gross margin and consistent quarterly EPS outperformance. Recent AI cybersecurity initiatives and partner expansions fuel positive sentiment, with a consensus price target of $133.25 implying upside potential.

The outlook remains favorable given AI-driven growth catalysts and solid cash flow, though elevated valuation ratios and competitive pressures pose risks. Analyst consensus leans bullish with 52% buy ratings, supporting a constructive view for investors seeking exposure to networking and cybersecurity trends.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cisco Systems Inc

Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.

Read more on CSCO

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN